Scientists Demonstrate Genetic Variant Is Linked To Effectiveness Of Smoking Cessation Medication
Smoking Cessation Medication
A genetic variant present in nearly half of Americans of European ancestry is linked to greater effectiveness of the smoking cessation medication bupropion (Zyban), according to research by scientists supported by the National Institute on Drug Abuse (NIDA) and the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). People with this variant were less likely than those without it to have resumed smoking six months after treatment with bupropion.
The study, published in the September issue of the journal Biological Psychiatry, is a step toward the goal of being able to tailor smoking cessation treatment to individuals based on their unique genetic make-up.
"This study is part of our ongoing commitment to develop more accurate and personalized approaches to medicine," said NIH Director Dr. Elias A. Zerhouni. "This kind of genetic research is helping us to better understand why some people respond to certain smoking cessation treatments, and others don't."
The study involved more than 300 smokers who had been randomly assigned to treatment with either bupropion or a placebo (sugar pill) for 10 weeks. Participants were genetically tested for the presence of a variant form of the CYP2B6 gene. The study was co-led by Dr. Rachel F. Tyndale of the Center for Addiction and Mental Health at the University of Toronto, Canada, and Dr. Caryn Lerman of the Transdisciplinary Tobacco Use Research Center at the University of Pennsylvania (TTURC) in Philadelphia.
"After 10 weeks of treatment, participants with this variant had significantly better quit rates on bupropion than on placebo, whereas those without it did equally well on both placebo and bupropion," says Dr. Tyndale. "Additionally, among all participants who took bupropion, those with this variant were less likely than those without it to have resumed smoking at the six month follow-up."
"This is another step towards improving the success rates of smoking cessation programs," says NIDA Director Dr. Nora D. Volkow. "We are that much closer to being able to choose the treatment that will most benefit the individual patient, based on their genetic make-up."
Previous studies have shown that about 45 percent of Americans of European ancestry have this variant form of the CYP2B6 gene. This variant is also found in about 50 percent of African Americans and 25 percent of Asian Americans. The current study looked only at people of European ancestry, but the author and her colleagues have begun a similar study in African American smokers. They hypothesize that this variant of the CYP2B6 gene will influence the effectiveness of bupropion treatment in the same way in African Americans as in those of European descent.
The Transdisciplinary Tobacco Use Research Centers are funded by NIDA, NCI and the National Institute on Alcohol Abuse and Alcoholism (NIAAA). Additional support for this study was provided by the Canadian Institute of Health Research.